Sunshine Biopharma (SBFM) POS AM 6 Nov 24 Prospectus update (post-effective amendment) Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2024
Entity Addresses [Line Items]
Document Type	S-1
Amendment Flag	true
Amendment Description	Post-Effective Amendment No. 1
Entity Registrant Name	Sunshine Biopharma Inc.
Entity Central Index Key	0001402328
Entity Tax Identification Number	20-5566275
Entity Incorporation, State or Country Code	CO
City Area Code	(954)
Local Phone Number	330-0684
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	333 Las Olas Way, CU4 Suite 433
Entity Address, City or Town	Fort Lauderdale
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33301

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 12,206,655	$ 16,292,347
Accounts receivable	3,218,682	2,552,362
Inventory	9,820,730	5,734,755
Prepaid expenses	735,796	310,591
Total Current Assets	25,981,863	24,890,055
Long-Term Assets:
Property & equipment	590,801	365,868
Intangible assets	2,942,684	1,444,259
Right-of-use-asset	541,468	646,779
Total Long-Term Assets	4,074,953	2,456,906
TOTAL ASSETS	30,056,816	27,346,961
Current Liabilities:
Accounts payable & accrued expenses	4,157,253	2,585,466
Earnout payable	0	2,547,831
Income tax payable	254,971	299,869
Current portion - right-of-use-liability	116,253	118,670
Total Current Liabilities	4,528,477	5,551,836
Long-Term Liabilities:
Deferred tax liability	48,729	48,729
Right-of-use-liability	440,298	539,035
Total Long-Term Liabilities	489,027	587,764
TOTAL LIABILITIES	5,017,504	6,139,600
SHAREHOLDERS' EQUITY
Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 130,000 and 10,000 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	13,000	1,000
Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 1,999,660 and 14,012 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	2,000	14
Capital paid in excess of par value	91,737,284	84,415,900
Accumulated comprehensive income	168,590	696,105
Accumulated (Deficit)	(66,881,562)	(63,905,658)
TOTAL SHAREHOLDERS' EQUITY	25,039,312	21,207,361
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 30,056,816	$ 27,346,961

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	3,000,000,000	3,000,000,000
Common Stock, Shares, Outstanding	1,999,660	14,012
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share		$ 0.10
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Outstanding	130,000	10,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Sales	$ 8,435,178	$ 5,957,668	$ 25,279,291	$ 16,412,586
Cost of sales	5,569,027	3,967,412	17,702,546	10,641,461
Gross profit	2,866,151	1,990,256	7,576,745	5,771,125
General & Administrative Expenses:
Accounting	124,772	56,350	565,172	301,381
Consulting	475,032	221,781	576,481	745,850
Director fees	100,000	100,000	300,000	300,000
Legal	118,311	133,302	563,745	392,874
Marketing	282,745	241,897	737,116	502,987
Office	530,334	544,215	2,203,970	1,422,058
R&D	126,362	238,012	784,630	1,039,502
Salaries	2,093,850	1,144,377	5,183,738	4,344,801
Taxes	56,471	52,586	278,177	212,953
Depreciation	64,627	37,210	158,115	106,797
Total General & Administrative Expenses:	3,972,504	2,769,730	11,351,144	9,369,203
(Loss) from operations	(1,106,353)	(779,474)	(3,774,399)	(3,598,078)
Other Income (Expense):
Foreign exchange (loss)	15,153	40	295,921	(206)
Interest income	108,614	207,431	396,698	624,361
Interest expense	0	(38,527)	(245)	(107,198)
Total Other Income (Expense)	123,767	168,944	692,374	516,957
Net (loss) before income taxes	(982,586)	(610,530)	(3,082,025)	(3,081,121)
Provision for income taxes	(215,217)	(40,952)	106,121	(174,899)
Net (Loss)	(1,197,803)	(651,482)	(2,975,904)	(3,256,020)
Comprehensive Income (Loss):
Gain (Loss) from foreign exchange translation	851,640	(460,507)	(527,515)	42,702
Comprehensive Income (Loss)	$ (346,163)	$ (1,111,989)	$ (3,503,419)	$ (3,213,318)
Basic and fully diluted (Loss) per common share	$ (0.94)	$ (50.72)	$ (13.61)	$ (265.71)
Weighted Average Common Shares Outstanding (Basic)	1,267,565	12,845	218,634	12,254

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows From Operating Activities:
Net (Loss)	$ (2,975,904)	$ (3,256,020)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	158,128	106,794
Foreign Exchange	0	(374)
Stock issued for services	12,000	0
Accounts receivable	(1,321,173)	(118,482)
Inventory	(4,201,955)	(1,221,112)
Prepaid expenses	251,391	247,977
Accounts Payable & accrued expenses	2,229,074	(587,973)
Earn-out payable	(2,547,831)	(172,076)
Income tax payable	(727,628)	(1,084,169)
Net Cash Flows (Used In) Operating Activities	(9,123,898)	(6,085,435)
Cash Flows From Investing Activities:
Reduction in right-of-use asset	92,231	97,498
Purchase of intangible assets	(327,088)	(19,804)
Purchase of equipment	(1,554,455)	(464,614)
Net Cash Flows (Used In) Investing Activities	(1,789,312)	(386,920)
Cash Flows From Financing Activities:
Proceeds from public offering net (common stock)	8,522,411	4,089,218
Exercise of warrants	1,940,610	1,156
Purchase of treasury stock	(3,139,651)	(541,143)
Lease liability	(87,852)	(93,125)
Net Cash Flows Provided by Financing Activities	7,235,518	3,456,106
Cash and Cash Equivalents at Beginning of Period	16,292,347	21,826,437
Net increase (decrease) in cash and cash equivalents	(3,677,692)	(3,016,249)
Foreign currency translation adjustment	(408,000)	35,952
Cash and Cash Equivalents at End of Period	12,206,655	18,846,140
Supplementary Disclosure of Cash Flow Information:
Cash paid for income taxes	956,012	0
Stock issued for services	$ 12,000	$ 0

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Preferred Stock [Member]	Comprehensive Income [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2022	$ 11	$ 80,864,326		$ 1,000	$ 161,847	$ (59,399,614)	$ 21,627,570
Beginning balance, shares at Dec. 31, 2022	11,293			10,000
Ending balance, value at Jun. 30, 2023	$ 13	84,447,876		$ 1,000	665,056	(62,004,152)	23,109,793
Beginning balance, shares at Jun. 30, 2023	12,873			10,000
Beginning balance, value at Dec. 31, 2022	$ 11	80,864,326		$ 1,000	161,847	(59,399,614)	21,627,570
Beginning balance, shares at Dec. 31, 2022	11,293			10,000
Repurchase stock		(541,143)					(541,143)
Exercise of warrants	$ 1	1,155					1,156
Beginning balance, shares	578
Net (loss)					42,702	(3,256,020)	(3,213,318)
Common stock and prefunded warrants issued in a private offering	$ 1	4,089,217					4,089,218
Beginning balance, shares	1,225
Beginning balance, shares	(257)
Ending balance, value at Sep. 30, 2023	$ 13	84,413,555		$ 1,000	204,549	(62,655,634)	21,963,483
Beginning balance, shares at Sep. 30, 2023	12,839			10,000
Beginning balance, value at Jun. 30, 2023	$ 13	84,447,876		$ 1,000	665,056	(62,004,152)	23,109,793
Beginning balance, shares at Jun. 30, 2023	12,873			10,000
Repurchase stock		(34,321)					(34,321)
Net (loss)					(460,507)	(651,482)	(1,111,989)
Beginning balance, shares	(34)
Ending balance, value at Sep. 30, 2023	$ 13	84,413,555		$ 1,000	204,549	(62,655,634)	21,963,483
Beginning balance, shares at Sep. 30, 2023	12,839			10,000
Beginning balance, value at Dec. 31, 2023	$ 14	84,415,900		$ 1,000	696,105	(63,905,658)	21,207,361
Beginning balance, shares at Dec. 31, 2023	14,012			10,000
Preferred Stock issued to related party				$ 12,000			12,000
Beginning balance, shares				120,000
Common stock and pre-funded warrants issued in an underwritten offering	$ 13	8,522,398					8,522,411
Beginning balance, shares	13,214
Exercise of warrants	$ 1,973	1,938,637					1,940,610
Beginning balance, shares	1,972,434
Repurchase of warrants		(3,139,651)					(3,139,651)
Net (loss)					(527,515)	(2,975,904)	(3,503,419)
Ending balance, value at Sep. 30, 2024	$ 2,000	91,737,284		$ 13,000	168,590	(66,881,562)	25,039,312
Beginning balance, shares at Sep. 30, 2024	1,999,660			130,000
Beginning balance, value at Jun. 30, 2024	$ 1,171	89,842,503		$ 13,000	(683,050)	(65,683,759)	23,489,865
Beginning balance, shares at Jun. 30, 2024	1,170,510			130,000
Exercise of warrants	$ 829	1,894,781					1,895,610
Beginning balance, shares	829,150
Net (loss)					851,640	(1,197,803)	(346,163)
Ending balance, value at Sep. 30, 2024	$ 2,000	$ 91,737,284		$ 13,000	$ 168,590	$ (66,881,562)	$ 25,039,312
Beginning balance, shares at Sep. 30, 2024	1,999,660			130,000

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business The Company was incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective October 15, 2009, the Company acquired Sunshine Biopharma Inc. in a transaction classified as a reverse acquisition. Upon completion of the reverse acquisition, the Company changed its name to Sunshine Biopharma Inc. and began operating as a pharmaceutical company. Sunshine Biopharma operates two wholly owned subsidiaries: (i) Nora Pharma Inc. (“Nora Pharma”), a Canadian corporation with a portfolio of pharmaceutical products consisting of 63 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian corporation which develops and sells nonprescription over-the-counter (“OTC”) products. The Company has determined that it has two reportable segments: · Prescription Generic Pharmaceuticals (“Generic Pharmaceuticals”) · Nonprescription Over-The-Counter Products (“OTC Products) Through September 30, 2024, sales from the Generic Pharmaceuticals segment represented approximately 97 % of total revenues of the Company while the remaining approximately 3 % was generated from the sale of OTC Products. Based on these results, the Company deems segmentation reporting to be immaterial at September 30, 2024. The Company is not subject to material customer concentration risks as it sells its products directly to pharmacies in several Canadian provinces. However, in Canada provincial governments reimburse patients for their prescription drugs expenditures to various degrees under drug reimbursement programs, making generic drugs prices highly dependent on governmental policies which may change over time. The most recent negotiations between the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association resulted in updated generic pricing for certain products which took effect on October 1, 2023. The updated prices are valid for three years and the agreement may be extended for an additional two years. In addition, the Company is engaged in the development of the following proprietary drugs: · Adva-27a, a small chemotherapy molecule for treatment of pancreatic cancer (IND-enabling studies were paused on November 2, 2023) · K1.1 mRNA, a lipid nano-particle (LNP) targeted for liver cancer · SBFM-PL4, a protease inhibitor for treatment of SARS Coronavirus infections

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Note 2 – Basis of Presentation The unaudited consolidated financial statements of the Company for the three and nine month periods ended September 30, 2024 and 2023, have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2023, was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024. These financial statements should be read in conjunction with that report. On April 17, 2024 and August 8, 2024, the Company completed 1-for-100 and 1-for-20 reverse splits of its common stock, respectively (the “Reverse Splits”). The share amounts, warrants, and related parameters specified in this report have been adjusted to reflect both Reverse Splits on a retroactive basis.

Underwritten Public Offering

Underwritten Public Offering	9 Months Ended
	Sep. 30, 2024
Underwritten Public Offering
Underwritten Public Offering	Note 3 – Underwritten Public Offering On February 15, 2024, the Company completed an underwritten public offering for gross proceeds of approximately $ 10 million, before deducting fees to the underwriter and other offering expenses payable by the Company. The net proceeds received by the Company were $ 8,522,411 . The offering consisted of 35,714 Units, consisting of (i) 13,214 Common Units, with each Common Unit consisting of one share of common stock, one-tenth of a Series A warrant to purchase one share of common stock (“Series A Warrant”) and two-tenths of a Series B warrant to purchase one share of common stock (“Series B Warrant”), and (ii) 22,500 Pre-Funded Units, with each Pre-Funded Unit consisting of one pre-funded warrant to purchase one share of common stock (“Pre-Funded Warrants”), one-tenth of a Series A Warrant and two-tenths of a Series B Warrant. The public offering price was $280 per Common Unit and $278 per Pre-Funded Unit. The Pre-Funded Warrants have an exercise price of $2.00 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. The initial exercise price of each Series A Warrant was $4,200 per share of common stock or pursuant to an alternative cashless exercise option. Under the alternative cashless exercise provision, which became effective following stockholder approval in March 2024, each Series A Warrant was exercisable on a cashless basis for two shares of common stock. The Series A Warrants were exercisable immediately and expire 30 months after the initial issuance date. The initial exercise price of each Series B Warrant was $4,760 per share of common stock. The Series B Warrants are exercisable immediately and expire 60 months after the initial issuance date. In addition (effective following stockholder approval), the Series A Warrants and Series B Warrants included a provision under which, following a reverse split of the common stock, the exercise price will be adjusted to the lowest volume weighted average price (“VWAP”) for the five trading days immediately preceding and immediately following the date of reverse stock split, and the number of shares issuable upon exercise of the Series A Warrants or Series B Warrants will be adjusted such that the aggregate exercise price of the Series A Warrants or Series B Warrants will remain unchanged. The Series B Warrants do not include an alternate cashless exercise provision and can only be exercised for cash so long as the Company’s registration statement for the underlying shares remains effective. In addition, the Company granted the underwriter, Aegis Capital Corp. ("Aegis"), a 45-day option to purchase up to an additional 15% of the total number of shares of common stock and/or Pre-Funded Warrants and/or Series A Warrants and/or Series B Warrants sold in the offering, solely to cover overallotments, if any. On February 15, 2024, Aegis partially exercised its over-allotment option for a total of 415 Series A Warrants and 830 Series B Warrants. On February 13, 2024, the Company obtained stockholder approval for (i) adjustment of the number of underlying shares and exercise price for both the Series A Warrants and the Series B warrants, and (ii) the alternate cashless exercise provision for the Series A warrants. As of September 30, 2024, all of the Pre-Funded Warrants, all of the Series A warrants, and 678,865 Series B Warrants have been exercised resulting in the Company issuing 22,500 , 1,120,784 , and 678,865 shares of common stock, respectively. In connection with such exercises, the Company received net proceeds of $ 45,000 , $ 0 , and $ 1,892,608 , respectively. As of September 30, 2024, the only warrants remaining outstanding in connection with this offering are 12,934,062 Series B Warrants exercisable at $ 2.7879 per share. The exercise price and number of underlying shares under the Series B Warrants are subject to further adjustments.

Acquisition of Nora Pharma Inc.

Acquisition of Nora Pharma Inc.	9 Months Ended
	Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisition of Nora Pharma Inc.	Note 4 – Acquisition of Nora Pharma Inc. On October 20, 2022, the Company acquired all of the issued and outstanding shares of Nora Pharma Inc. (“Nora Pharma”), a Canadian privately held pharmaceutical company. The purchase price for the shares was $ 18,860,637 , $ 14,346,637 of which was paid in cash and the remainder was paid through the issuance of 1,850 shares of the Company’s common stock valued at $ 4,514,000 or $2,440 per share. Nora Pharma sells generic pharmaceutical products in Canada. Nora Pharma’s operations are authorized by a Drug Establishment License issued by Health Canada. The following table summarizes the allocation of the purchase price as of October 20, 2022, the acquisition date using Nora Pharma’s balance sheet assets and liabilities: Schedule of allocation of purchase price Accounts receivable $ 1,358,121 Inventory 3,181,916 Intangible assets 659,571 Equipment & furniture 210,503 Other assets 1,105,093 Total assets 6,515,204 Liabilities assumed (5,981,286 ) Net assets 533,918 Goodwill 18,326,719 Total Consideration $ 18,860,637 The value of the 1,850 shares issued as part of the consideration paid for Nora Pharma was determined based on the reverse splits adjusted closing market price of the Company’s common stock on the acquisition date, October 20, 2022 ($2,440 per share). See Note 6 – Reverse Stock Splits The Company impaired 100% of the goodwill amount in 2022 and plans to depreciate the intangible assets as detailed in Note 5 below. As part of the consideration paid for Nora Pharma, the Company agreed to a $ 5,000,000 CAD ($ 3,632,000 USD) earn-out payable to Mr. Malek Chamoun, the Seller of Nora Pharma and its current President. The earnout is payable in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales (as defined in the Purchase Agreement) above Nora Pharma’s June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant to the Company’s employment agreement with him. The total earn-out amount of $3,632,000 has been recorded as a salary payable. During the fiscal year ended December 31, 2023, the Company paid an earn-out of $ 1,084,169 for the fiscal year ended December 31, 2022. On April 22, 2024, the Company paid an earn-out of $ 3,093,878 CAD (approximately $ 2,291,761 USD) for the earn-out realized in fiscal year 2023. The current remaining earn-out balance is $ 479,207 CAD (approximately $ 354,968 USD).

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 5 – Intangible Assets Intangible assets, net consisted of the following: Schedule of intangible assets September 30, December 31, Balance at beginning of the year $ 1,444,259 776,856 Purchase of additional intangible assets (licenses) 1,594,373 710,372 Total 3,038,632 1,487,228 Less accumulated amortization (95,948 ) (42,969 ) Finite-lived intangible assets, net $ 2,942,684 $ 1,444,259 As of September 30, 2024, the estimated amortization amounts of the Company’s intangible assets for each of the next five years are as follows: Schedule of estimated amortization expense 2025 $ 105,462 2026 105,462 2027 105,462 2028 71,032 2029 19,621

Reverse Stock Splits

Reverse Stock Splits	9 Months Ended
	Sep. 30, 2024
Reverse Stock Splits
Reverse Stock Splits	Note 6 – Reverse Stock Splits Effective April 17, 2024 and August 8, 2024, the Company completed 1-for-100 and 1-for-20 reverse splits of its common stock, respectively. The Company had previously completed three (3) reverse stock splits including a 1-for-200 reverse split on February 9, 2022, and two 1-for-20 reverse splits, one in 2019 and the other in 2020. The Company’s financial statements included in this report reflect all five (5) reverse stock splits on a retroactive basis for all periods presented and for all references to common stock, unless specifically stated otherwise.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Capital Stock	Note 7 – Capital Stock The Company’s authorized capital is comprised of 3,000,000,000 shares of common stock, par value $ 0.001 , and 30,000,000 shares of preferred stock, $ 0.10 par value. As of September 30, 2024, the Company had authorized 1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock is non-convertible and non-redeemable. It has a liquidation preference equal to the stated value of $0.10 per share, relative to the common stock and gives the holder the right to 1,000 votes per share. As of September 30, 2024, 130,000 shares of Series B Preferred Stock were outstanding and held by the Company’s Chief Executive Officer. On February 17, 2022, the Company completed a public offering and received net proceeds of $ 6,833,071 from the offering. Pursuant to the public offering, the Company issued and sold an aggregate of 941 shares of common stock and 20,051 warrants to purchase shares of common stock (the “Tradeable Warrants”). On October 12, 2023, the Company held a special meeting of the holders of the outstanding Tradeable Warrants in which the holders of the majority of the outstanding Tradeable Warrants approved an amendment to the Warrant Agent Agreement to eliminate the provision that prohibited the Company’s CEO from exercising his voting rights under the Series B Preferred Stock, as well as to lower the exercise price of the Tradeable Warrants from $4,440 to $220. The Company entered into the amendment to the Warrant Agent Agreement on October 18, 2023. On March 14, 2022, the Company completed a private placement and received net proceeds of $ 6,781,199 . In connection with this private placement, the Company issued (i) 1,150 shares of its common stock together with investor warrants (“Investor Warrants”) to purchase up to 1,150 shares of common stock, and (ii) 651 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor Warrants to purchase up to 6,511 shares of common stock. Each share of common stock and accompanying Investor Warrant was sold together at a combined offering price of $4,440 and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined offering price of $4,438. The Pre-Funded Warrants were immediately exercisable, at an exercise price of $2.00, and could be exercised at any time until all of the Pre-Funded Warrants were exercised in full. The Investor Warrants have an exercise price of $4,440 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance. On April 28, 2022, the Company completed another private placement and received net proceeds of $ 16,752,915 . In connection with this private placement, the Company issued (i) 1,236 shares of its common stock together with warrants (“April Warrants”) to purchase up to 2,472 shares of common stock, and (ii) 1,195 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with April Warrants to purchase up to 2,390 shares of common stock. Each share of common stock and accompanying two April Warrants were sold together at a combined offering price of $8,020 and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $8,018. The Pre-Funded Warrants were immediately exercisable, at an exercise price of $2.00, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise price of $7,520 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance. On October 20, 2022, the Company issued 1,850 shares of common stock as part of the acquisition of Nora Pharma. These shares were valued at $ 4,514,000 , or $2,440 per share. On January 19, 2023, the Company announced a stock repurchase program of up to $ 2 million (“Stock Repurchase Program”). During the six months ended June 30, 2023, the Company repurchased a total of 2,228 shares of common stock at an average price of $2,274.20 per share for a total cost of $ 506,822 . The 2,228 repurchased shares were cancelled and returned to treasury reducing the number of issued and outstanding shares from 11,292 to 9,064. On May 16, 2023, the Company completed a private placement pursuant to a securities purchase agreement with an institutional investor for gross proceeds of approximately $ 5 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The net proceeds received by the Company were $ 4,089,218 . In connection with the private placement, the Company issued (i) 1,225 shares of common stock, (ii) 1,751 pre-funded warrants (the “May Pre-Funded Warrants”), and (iii) investor warrants (the “May Warrants”) to purchase up to 5,952 shares of common stock. Each share of common stock and accompanying two May Warrants were sold together at a combined offering price of $1,680 and each May Pre-Funded Warrant and accompanying two May Warrants were sold together at a combined offering price of $1,678. The May Pre-Funded Warrants are immediately exercisable, at an exercise price of $2.00, and may be exercised at any time until all of the May Pre-Funded Warrants are exercised in full. The May Warrants have an exercise price of $1,180 per share (subject to adjustment as set forth therein), are exercisable upon issuance and will expire five and a half years from the date of issuance. In 2022 and 2023, the Company issued a total of 5,396 shares of common stock in connection with warrant exercises for aggregate net proceeds of $ 13,196,681 . In July 2023, the Company repurchased a total of 34 shares of common stock under the Stock Repurchase Program announced on January 19, 2023, at an average price of $1,009.20 per share for a total cost of $ 34,321 . In October 2023, the 34 repurchased shares were cancelled and returned to treasury reducing the number of issued and outstanding shares from 12,873 to 12,839. On November 16, 2023, the Company issued 1,173 shares of common stock and received net proceeds of $ 2,346 in connection with the exercise of all 1,173 remaining May Pre-Funded Warrants at an exercise price of $2.00 per share. On February 8, 2024, the Company issued 20,000 shares of Series B Preferred Stock to the Company’s CEO for a purchase price of $ 0.10 per share. On February 15, 2024, the Company completed an underwritten public offering and in connection therewith it issued an aggregate of 35,714 shares of common stock, of which 22,500 shares were issued in connection with pre-funded warrant exercises. On March 4, 2024, the Company issued 100,000 shares of Series B Preferred Stock to the Company’s CEO for a purchase price of $ 0.10 per share. On April 17, 2024, the Company completed a 1-for-100 reverse split of its common stock. In April and May 2024, the Company issued 1,120,784 shares of common stock in connection with the cashless exercise of all of the Series A Warrants and received $ 0 in net proceeds. On August 16, 2024, the Company issued 150,285 shares of common stock in connection with the rounding up of fractional shares following the reverse stock splits of April 17, 2024 and August 8, 2024. In August and September 2024, the Company issued 678,865 shares of common stock in connection with the exercise of 678,865 Series B Warrants and received aggregate net proceed of $ 1,892,608 . As of September 30, 2024 and December 31, 2023, the Company had a total of 1,999,660 and 14,012 shares of common stock issued and outstanding, respectively. The Company has declared no dividends since inception.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2024
Warrants
Warrants	Note 8 – Warrants The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. In 2022, 2023, and during the nine months ended September 30, 2024, the Company completed five (5) financing events, and in connection therewith, it issued warrants as follows: Schedule of warrants issued with financing Type Number Exercise Price Expiry Date 2022 Pre-Funded Warrants 1,846 $2.00 Unlimited Tradeable Warrants 2,051 $4,440.00 February 2027 Investor Warrants 1,801 $4,440.00 March 2027 April Warrants 4,862 $7,520.00 April 2027 May Pre-Funded Warrants 1,751 $2.00 Unlimited May Investor Warrants 5,952 $1,180.00 November 2028 2024 Pre-Funded Warrants 22,500 $2.00 Unlimited Series A Warrants 3,986 * $ 4,200.00 * August 2026 Series B Warrants 7,973 * $ 4,760.00 * February 2029 * Subject to adjustments per the Series A and Series B Warrant Agreements. As of September 30, 2024, all of the 2022 Pre-Funded Warrants, all of the May Pre-Funded Warrants, all of the 2024 Pre-Funded Warrants, a total of 1,569 Tradeable Warrants, 1,401 Investor Warrants, all of the Series A Warrants, and 678,865 Series B Warrants were exercised resulting in aggregate net proceeds of $ 15,134,289 received by the Company. On February 11, 2024, the Company redeemed all of the April Warrants and all of the May Investor Warrants for an aggregate purchase price of $ 3,139,651 . The Company’s outstanding warrants as of September 30, 2024 consisted of the following: Schedule of warrants outstanding Type Number Exercise Price Expiry Date Tradeable Warrants 481 $220.00 February 2027 Investor Warrants 400 $4,440.00 March 2027 Series B Warrants 12,934,062 * $ 2.7879 * February 2029 * As adjusted and subject to further adjustments per the Series B Warrant Agreements.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Note 9 – Earnings Per Share The following table sets forth the computation of basic and diluted net income per share for the quarters ended September 30: Schedule of computation of basic and diluted net income per share 2024 2023 Net gain (loss) attributable to common stock $ (1,197,803 ) $ (651,482 ) Basic weighted average outstanding shares of common stock 1,267,565 12,845 Dilutive common share equivalents – – Dilutive weighted average outstanding shares of common stock 1,267,565 12,845 Net gain (loss) per share attributable to common stock $ (0.94 ) $ (50.72 )

Lease

Lease	9 Months Ended
	Sep. 30, 2024
Lease
Lease	Note 10 – Lease The Company has obligations as a lessee for office and warehouse space with initial non-cancellable terms in excess of one year. The Company classified the lease as an operating lease. The lease contains a renewal option for a period of five years. Because the Company is certain to exercise the renewal option, the optional period is included in determining the lease term, and associated payments under the renewal option are included in the lease payments. The Company’s lease does not include termination options for either party to the lease or restrictive financial or other covenants. Payments due under the lease include fixed payments plus a variable payment. The Company’s lease requires it to make variable payments for the Company’s proportionate share of building’s property taxes, insurance, and common area maintenance. These variable lease payments are not included in lease payments used to determine lease liability and are recognized as variable costs when incurred. Amounts reported on the balance sheet as of September 30, 2024, were as follows: Schedule of lease information Operating lease ROU asset $541,468 Operating lease liability - Short-term $116,253 Operating lease liability - Long-term $440,298 Remaining lease term 5 years 3 months Discount rate 6 % Amounts disclosed for ROU assets obtained in exchange for lease obligations and reductions of ROU assets resulting from reductions of lease obligations include amounts reduced from the carrying amount of ROU assets resulting from deferred rent. Maturities of lease liabilities under non-cancellable operating leases at September 30, 2024 are as follows: Schedule of maturities of lease liabilities 2024 $ 28,418 2025 $ 116,458 2026 $ 110,305 2027 $ 103,897 2028 $ 97,861 Thereafter $ 99,611

Management and Director Compens

Management and Director Compensation	9 Months Ended
	Sep. 30, 2024
Management And Director Compensation
Management and Director Compensation	Note 11 – Management and Director Compensation The Company paid its officers cash compensation totaling $ 240,176 and $ 245,000 , and $ 1,595,711 and $ 1,290,000 for the three- and nine-month periods ended September 30, 2024 and 2023, respectively. Of the $1,595,711 amount, $ 400,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company. The Company paid its directors aggregate cash compensation totaling $ 100,000 for each of the three months periods ended September 30, 2024 and 2023, and $ 300,000 for each of the nine-month periods ended September 30, 2024 and 2023.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 12 – Income Taxes Our Income tax (expense) / benefit of $ (130,551) and $ 190,787 for the three and nine months ended September 30, 2024, respectively, is primarily due to operations outside of the United States and changes in valuation allowance related to certain deferred tax assets generated or utilized in the applicable period. Our income tax (expense) of $ (40,952) and $ (174,899) for the three and nine months ended September 30, 2023, respectively, is primarily due to operations outside of the United States and changes in valuation allowance related to certain deferred tax assets generated or utilized in the applicable period. Deferred tax assets are regularly reviewed for recoverability by jurisdiction and valuation allowances are established based on historical and projected future taxable losses and the expected timing of the reversal of existing temporary differences. The Company has recorded valuation allowances against the majority of its deferred tax assets of September 30, 2024, and the Company expects to maintain these valuation allowances until there is sufficient evidence that future earnings can be achieved, which is uncertain at this time. The Company's consolidated financial statements contain various tax related entries the same being due to the operations of the two Canadian subsidiaries and are in compliance with Canadian tax laws.

Acquisition of Nora Pharma In_2

Acquisition of Nora Pharma Inc. (Tables)	9 Months Ended
	Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of allocation of purchase price	Schedule of allocation of purchase price Accounts receivable $ 1,358,121 Inventory 3,181,916 Intangible assets 659,571 Equipment & furniture 210,503 Other assets 1,105,093 Total assets 6,515,204 Liabilities assumed (5,981,286 ) Net assets 533,918 Goodwill 18,326,719 Total Consideration $ 18,860,637

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Schedule of intangible assets September 30, December 31, Balance at beginning of the year $ 1,444,259 776,856 Purchase of additional intangible assets (licenses) 1,594,373 710,372 Total 3,038,632 1,487,228 Less accumulated amortization (95,948 ) (42,969 ) Finite-lived intangible assets, net $ 2,942,684 $ 1,444,259

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2024
Warrants
Schedule of warrants issued with financing	Schedule of warrants issued with financing Type Number Exercise Price Expiry Date 2022 Pre-Funded Warrants 1,846 $2.00 Unlimited Tradeable Warrants 2,051 $4,440.00 February 2027 Investor Warrants 1,801 $4,440.00 March 2027 April Warrants 4,862 $7,520.00 April 2027 May Pre-Funded Warrants 1,751 $2.00 Unlimited May Investor Warrants 5,952 $1,180.00 November 2028 2024 Pre-Funded Warrants 22,500 $2.00 Unlimited Series A Warrants 3,986 * $ 4,200.00 * August 2026 Series B Warrants 7,973 * $ 4,760.00 * February 2029 * Subject to adjustments per the Series A and Series B Warrant Agreements.
Schedule of warrants outstanding	Schedule of warrants outstanding Type Number Exercise Price Expiry Date Tradeable Warrants 481 $220.00 February 2027 Investor Warrants 400 $4,440.00 March 2027 Series B Warrants 12,934,062 * $ 2.7879 * February 2029 * As adjusted and subject to further adjustments per the Series B Warrant Agreements.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of computation of basic and diluted net income per share	Schedule of computation of basic and diluted net income per share 2024 2023 Net gain (loss) attributable to common stock $ (1,197,803 ) $ (651,482 ) Basic weighted average outstanding shares of common stock 1,267,565 12,845 Dilutive common share equivalents – – Dilutive weighted average outstanding shares of common stock 1,267,565 12,845 Net gain (loss) per share attributable to common stock $ (0.94 ) $ (50.72 )

Lease (Tables)

Lease (Tables)	9 Months Ended
	Sep. 30, 2024
Lease
Schedule of lease information	Schedule of lease information Operating lease ROU asset $541,468 Operating lease liability - Short-term $116,253 Operating lease liability - Long-term $440,298 Remaining lease term 5 years 3 months Discount rate 6 %
Schedule of maturities of lease liabilities	Schedule of maturities of lease liabilities 2024 $ 28,418 2025 $ 116,458 2026 $ 110,305 2027 $ 103,897 2028 $ 97,861 Thereafter $ 99,611

Description of Business (Detail

Description of Business (Details Narrative) - Revenue Benchmark [Member] - Product Concentration Risk [Member]	9 Months Ended
	Sep. 30, 2024
Generic Pharmaceuticals [Member]
Product Information [Line Items]
Concentration Risk, Percentage	97%
OTC Products [Member]
Product Information [Line Items]
Concentration Risk, Percentage	3%

Basis of Presentation (Details

Basis of Presentation (Details Narrative)	Aug. 08, 2024	Apr. 17, 2024
Accounting Policies [Abstract]
Stockholders' Equity, Reverse Stock Split	1-for-20	1-for-100

Underwritten Public Offering (D

Underwritten Public Offering (Details Narrative) - USD ($)		9 Months Ended
	Feb. 15, 2024	Sep. 30, 2024	Sep. 30, 2023
Securities Financing Transaction [Line Items]
Proceeds from Warrant Exercises		$ 1,940,610	$ 1,156
Series A Warrants [Member]
Securities Financing Transaction [Line Items]
Conversion of Stock, Shares Issued		1,120,784
Proceeds from Warrant Exercises		$ 0
Series B Warrants [Member]
Securities Financing Transaction [Line Items]
[custom:WarrantsExercised]		678,865
Conversion of Stock, Shares Issued		678,865
Proceeds from Warrant Exercises		$ 1,892,608
Pre Funded Warrants [Member]
Securities Financing Transaction [Line Items]
Conversion of Stock, Shares Issued		22,500
Proceeds from Warrant Exercises		$ 45,000
February 2024 Public Offering [Member]
Securities Financing Transaction [Line Items]
[custom:GrossProceedsFromIssuanceOrSaleOfEquity]	$ 10,000,000
Proceeds from Issuance or Sale of Equity	$ 8,522,411
[custom:UnitsDescription]		The offering consisted of 35,714 Units, consisting of (i) 13,214 Common Units, with each Common Unit consisting of one share of common stock, one-tenth of a Series A warrant to purchase one share of common stock (“Series A Warrant”) and two-tenths of a Series B warrant to purchase one share of common stock (“Series B Warrant”), and (ii) 22,500 Pre-Funded Units, with each Pre-Funded Unit consisting of one pre-funded warrant to purchase one share of common stock (“Pre-Funded Warrants”), one-tenth of a Series A Warrant and two-tenths of a Series B Warrant. The public offering price was $280 per Common Unit and $278 per Pre-Funded Unit. The Pre-Funded Warrants have an exercise price of $2.00 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. The initial exercise price of each Series A Warrant was $4,200 per share of common stock or pursuant to an alternative cashless exercise option. Under the alternative cashless exercise provision, which became effective following stockholder approval in March 2024, each Series A Warrant was exercisable on a cashless basis for two shares of common stock. The Series A Warrants were exercisable immediately and expire 30 months after the initial issuance date. The initial exercise price of each Series B Warrant was $4,760 per share of common stock. The Series B Warrants are exercisable immediately and expire 60 months after the initial issuance date.
February 2024 Public Offering [Member] | Series A Warrants [Member] | Over-Allotment Option [Member]
Securities Financing Transaction [Line Items]
[custom:WarrantsIssuedShares]	415
February 2024 Public Offering [Member] | Series B Warrants [Member]
Securities Financing Transaction [Line Items]
Class of Warrant or Right, Outstanding		12,934,062
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.7879
February 2024 Public Offering [Member] | Series B Warrants [Member] | Over-Allotment Option [Member]
Securities Financing Transaction [Line Items]
[custom:WarrantsIssuedShares]	830

Acquisition of Nora Pharma In_3

Acquisition of Nora Pharma Inc. (Details - Allocation purchase price) - Nora Pharma [Member]	Oct. 20, 2022 USD ($)
Business Acquisition [Line Items]
Business combination, account receivable	$ 1,358,121
Business combination, inventory	3,181,916
Business combination, intangible assets	659,571
Business combination, equipment and furniture	210,503
Business combination, other assets	1,105,093
Business combination, total assets	6,515,204
Business combination, liabilities assumed	(5,981,286)
Business combination, net assets	533,918
Business combination, goodwill	18,326,719
Business combination, total consideration	$ 18,860,637

Acquisition of Nora Pharma In_4

Acquisition of Nora Pharma Inc. (Details Narrative)				12 Months Ended
	Apr. 22, 2024 USD ($)	Apr. 22, 2024 CAD ($)	Oct. 20, 2022 USD ($) shares	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CAD ($)	Sep. 30, 2024 USD ($)	Oct. 20, 2022 CAD ($)
Business Acquisition [Line Items]
[custom:EarnoutPayable-0]				$ 2,547,831		$ 0
Nora Pharma [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred			$ 18,860,637
Payments to Acquire Businesses, Gross			$ 14,346,637
Stock Issued During Period, Shares, Acquisitions | shares			1,850
Stock Issued During Period, Value, Acquisitions			$ 4,514,000
[custom:EarnoutLiabilityExpenseFirstInstallment]	$ 2,291,761	$ 3,093,878
[custom:EarnoutLiabilityExpenseSecondInstallment]				354,968	$ 479,207
Nora Pharma [Member] | Malek Chamoun [Member]
Business Acquisition [Line Items]
[custom:EarnoutPayable-0]			$ 3,632,000				$ 5,000,000
[custom:PaymentOfEarnoutLiability]				$ 1,084,169

Intangible Assets (Details - In

Intangible Assets (Details - Intangible assets) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Finite lived intangible assets, beginning balance	$ 1,444,259	$ 776,856
Intangible assets additions	1,594,373	710,372
Finite lived intangible assets, ending balance	3,038,632	1,487,228
Less accumulated amortization	(95,948)	(42,969)
Finite lived intangible assets, net	$ 2,942,684	$ 1,444,259

Intangible Assets (Details Narr

Intangible Assets (Details Narrative)	Sep. 30, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 105,462
2026	105,462
2027	105,462
2028	71,032
2029	$ 19,621

Capital Stock (Details Narrativ

Capital Stock (Details Narrative) - USD ($)

1 Months Ended

2 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Aug. 16, 2024

Aug. 08, 2024

Apr. 17, 2024

Mar. 04, 2024

Feb. 15, 2024

Feb. 08, 2024

Nov. 16, 2023

Jul. 31, 2023

May 16, 2023

Oct. 20, 2022

Apr. 28, 2022

Mar. 14, 2022

Feb. 17, 2022

May 31, 2024

Sep. 30, 2024

Sep. 30, 2024

Jun. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Dec. 31, 2023

Jan. 19, 2023

Class of Stock [Line Items]

Common Stock, Shares Authorized

3,000,000,000

3,000,000,000

3,000,000,000

3,000,000,000

Common Stock, Par or Stated Value Per Share

$ 0.001

$ 0.001

$ 0.001

$ 0.001

Share Repurchase Program, Authorized, Amount

$ 2,000,000

Proceeds from Warrant Exercises

$ 1,940,610

$ 1,156

Stockholders' Equity, Reverse Stock Split

1-for-20

1-for-100

Stock Issued During Period, Value, Conversion of Convertible Securities

$ 1,895,610

$ 1,940,610

$ 1,156

Common Stock, Shares, Outstanding

1,999,660

1,999,660

1,999,660

14,012

Dividends

$ 0

May Pre-Funded Warrants [Member]

Class of Stock [Line Items]

[custom:StockIssuedDuringPeriodShareConversionOfConvertibleSecurities]

1,173

Proceeds from Warrant Exercises

$ 2,346

[custom:WarrantsExercised]

1,173

Pre Funded Warrants [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, Other

22,500

Series B Warrants [Member]

Class of Stock [Line Items]

Proceeds from Warrant Exercises

$ 1,892,608

Warrants Exercised [Member]

Class of Stock [Line Items]

[custom:StockIssuedDuringPeriodShareConversionOfConvertibleSecurities]

5,396

Proceeds from Warrant Exercises

$ 13,196,681

Nora Pharma Inc [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, Acquisitions

1,850

Stock Issued During Period, Value, Acquisitions

$ 4,514,000

Private Placement [Member]

Class of Stock [Line Items]

Proceeds from Issuance or Sale of Equity

$ 16,752,915

$ 6,781,199

Institutional Investor [Member]

Class of Stock [Line Items]

[custom:GrossProceedsFromIssuanceOfPrivatePlacement]

$ 5,000,000

Proceeds from Issuance of Private Placement

$ 4,089,218

Tradeable Warrants [Member]

Class of Stock [Line Items]

[custom:WarrantsIssuedShares]

2,051

Common Stock Member And Investor Warrants [Member] | Private Placement [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, New Issues

1,150

Investor Warrants [Member]

Class of Stock [Line Items]

[custom:WarrantsIssuedShares]

1,801

Common Stock Member And April Warrants [Member] | Private Placement [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, New Issues

1,236

April Warrants [Member]

Class of Stock [Line Items]

[custom:WarrantsIssuedShares]

4,862

May Investor Warrants [Member]

Class of Stock [Line Items]

[custom:WarrantsIssuedShares]

5,952

May Investor Warrants [Member] | Institutional Investor [Member]

Class of Stock [Line Items]

[custom:WarrantsIssuedDuringPeriodSharesNewIssues]

5,952

Public Offering [Member]

Class of Stock [Line Items]

Proceeds from Issuance or Sale of Equity

$ 6,833,071

Public Offering [Member] | Tradeable Warrants [Member]

Class of Stock [Line Items]

[custom:WarrantsIssuedShares]

20,051

Private Placement [Member] | Investor Warrants [Member]

Class of Stock [Line Items]

[custom:WarrantsIssuedShares]

1,150

Private Placement [Member] | Pre Funded Warrants [Member]

Class of Stock [Line Items]

[custom:WarrantsIssuedShares]

1,195

651

Private Placement [Member] | April Warrants [Member]

Class of Stock [Line Items]

[custom:WarrantsIssuedShares]

2,472

Preferred Stock [Member]

Class of Stock [Line Items]

Preferred Stock, Shares Authorized

30,000,000

30,000,000

30,000,000

Preferred Stock, Par or Stated Value Per Share

$ 0.10

$ 0.10

$ 0.10

Series B Preferred Stock [Member]

Class of Stock [Line Items]

Preferred Stock, Shares Authorized

1,000,000

1,000,000

1,000,000

1,000,000

Preferred Stock, Par or Stated Value Per Share

$ 0.10

Preferred Stock, Shares Outstanding

130,000

130,000

130,000

10,000

Series B Preferred Stock [Member] | Chief Executive Officer [Member]

Class of Stock [Line Items]

Preferred Stock, Shares Outstanding

130,000

130,000

130,000

Stock Issued During Period, Shares, Other

100,000

20,000

Share Price

$ 0.10

$ 0.10

Common Stock [Member]

Class of Stock [Line Items]

Stock Repurchased During Period, Shares

34

2,228

Payments for Repurchase of Equity

$ 34,321

$ 506,822

Stock Issued During Period, Shares, Other

35,714

Stockholders' Equity, Reverse Stock Split

1-for-100

Stock Issued During Period, Shares, Conversion of Convertible Securities

1,120,784

Stock Issued During Period, Value, Conversion of Convertible Securities

$ 0

Stock Issued During Period, Shares, Period Increase (Decrease)

150,285

Conversion of Stock, Shares Issued

678,865

Common Stock [Member] | Institutional Investor [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, New Issues

1,225

Common Stock [Member] | Public Offering [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, New Issues

941

Series B Warrants [Member]

Class of Stock [Line Items]

Proceeds from Warrant Exercises

$ 1,892,608

[custom:WarrantsExercised]

678,865

Conversion of Stock, Shares Issued

678,865

Conversion of Stock, Shares Converted

678,865

Warrants (Details - Warrants is

Warrants (Details - Warrants issued with financing)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
2022 Pre-Funded Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants issued | shares	1,846
Warrant exercise price | $ / shares	$ 2
[custom:WarrantExpirationDate]	Unlimited
Tradeable Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants issued | shares	2,051
Warrant exercise price | $ / shares	$ 4,440
[custom:WarrantExpirationDate]	February 2027
Investor Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants issued | shares	1,801
Warrant exercise price | $ / shares	$ 4,440
[custom:WarrantExpirationDate]	March 2027
April Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants issued | shares	4,862
Warrant exercise price | $ / shares	$ 7,520
[custom:WarrantExpirationDate]	April 2027
May Pre-Funded Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants issued | shares	1,751
Warrant exercise price | $ / shares	$ 2
[custom:WarrantExpirationDate]	Unlimited
May Investor Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants issued | shares	5,952
Warrant exercise price | $ / shares	$ 1,180
[custom:WarrantExpirationDate]	November 2028
2024 Pre-Funded Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants issued | shares	22,500
Warrant exercise price | $ / shares	$ 2
[custom:WarrantExpirationDate]	Unlimited
Series A Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants issued | shares	3,986	[1]
Warrant exercise price | $ / shares	$ 4,200	[1]
[custom:WarrantExpirationDate]	August 2026
Series B Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants issued | shares	7,973	[1]
Warrant exercise price | $ / shares	$ 4,760	[1]
[custom:WarrantExpirationDate]	February 2029
[1]Subject to adjustments per the Series A and Series B Warrant Agreements.

Warrants (Details - Warrants ou

Warrants (Details - Warrants outstanding)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Tradeable Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants outstanding | shares	481
Warrant exercise price | $ / shares	$ 220
[custom:WarrantExpirationDate]	February 2027
Investor Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants outstanding | shares	400
Warrant exercise price | $ / shares	$ 4,440
[custom:WarrantExpirationDate]	March 2027
Series B Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants outstanding | shares	12,934,062	[1]
Warrant exercise price | $ / shares	$ 2.7879	[1]
[custom:WarrantExpirationDate]	February 2029
[1]As adjusted and subject to further adjustments per the Series B Warrant Agreements.

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)		9 Months Ended
	Feb. 11, 2024	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from Warrant Exercises		$ 1,940,610	$ 1,156
Tradeable Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised		1,569
Investor Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised		1,401
Series B Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised		678,865
Proceeds from Warrant Exercises		$ 15,134,289
May Investor Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
[custom:AggregatePurchasePrice]	$ 3,139,651

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Net gain (loss) attributable to common stock	$ (1,197,803)	$ (651,482)
Basic weighted average outstanding shares of common stock	1,267,565	12,845	218,634	12,254
Dilutive common share equivalents	$ 0	$ 0
Dilutive weighted average outstanding shares of common stock	1,267,565	12,845
Net gain (loss) per share attributable to common stock	$ (0.94)	$ (50.72)	$ (13.61)	$ (265.71)

Lease (Details - Lease informat

Lease (Details - Lease information) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Lease
Operating Lease, Right-of-Use Asset	$ 541,468	$ 646,779
Operating Lease, Liability, Current	116,253	118,670
Operating Lease, Liability, Noncurrent	$ 440,298	$ 539,035
[custom:LesseeOperatingLeasesRemainingLeaseTerm]	5 years 3 months
Operating Lease, Weighted Average Discount Rate, Percent	6%

Lease (Details - Maturities of

Lease (Details - Maturities of lease payments)	Sep. 30, 2024 USD ($)
Lease
2024	$ 28,418
2025	116,458
2026	110,305
2027	103,897
2028	97,861
Thereafter	$ 99,611

Management and Director Compe_2

Management and Director Compensation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Salary and Wage, Officer, Excluding Cost of Good and Service Sold	$ 240,176	$ 245,000	$ 1,595,711	$ 1,290,000
Noninterest Expense Directors Fees	$ 100,000	$ 100,000	300,000	$ 300,000
Advanomics Corporation [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Salary and Wage, Officer, Excluding Cost of Good and Service Sold			$ 400,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Effective Income Tax Rate Reconciliation [Line Items]
Income Tax Expense (Benefit)	$ 215,217	$ 40,952	$ (106,121)	$ 174,899
UNITED STATES
Effective Income Tax Rate Reconciliation [Line Items]
Income Tax Expense (Benefit)	$ (130,551)	$ (40,952)	$ 190,787	$ (174,899)